Skye Bioscience, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Skye Bioscience, Inc. (SKYE) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$1.05 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2018-05-15
- Skye Bioscience, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-03-31 was -$1.05M.
- Skye Bioscience, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-12-31 was -$2.14M.
- Skye Bioscience, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-09-30 was -$66.88K.
- Skye Bioscience, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-06-30 was -$271.41K.
- Skye Bioscience, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$3.30M.
- Skye Bioscience, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$3.55M.
- Skye Bioscience, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$3.73M.
- Skye Bioscience, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$1.76M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 25 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 29 month |
|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$1.05M 10-Q · filed 2018-05-15 | -$3.20M derived: sum of 2 quarters · filed 2018-05-15 | -$3.26M derived: sum of 3 quarters · filed 2018-05-15 | -$3.53M derived: sum of 4 quarters · filed 2018-05-15 | |||
| 2017-12-31 | -$2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | -$2.21M derived: sum of 2 quarters · filed 2018-03-19 | -$2.48M derived: sum of 3 quarters · filed 2018-03-19 | -$3.30M 10-K · filed 2018-03-19 | |||
| 2017-09-30 | -$66.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$338.29K derived: sum of 2 quarters · filed 2017-11-14 | -$1.15M 10-Q · filed 2017-11-14 | -$1.82M derived: sum of 4 quarters · filed 2018-05-15 | |||
| 2017-06-30 | -$271.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | -$1.09M 10-Q · filed 2017-08-11 | -$1.75M derived: sum of 3 quarters · filed 2018-05-15 | -$2.26M derived: sum of 4 quarters · filed 2018-05-15 | |||
| 2017-03-31 | -$816.40K 10-Q · filed 2018-05-15 | -$1.48M derived: sum of 2 quarters · filed 2018-05-15 | -$1.99M derived: sum of 3 quarters · filed 2018-05-15 | -$3.22M derived: sum of 4 quarters · filed 2018-05-15 | |||
| 2016-12-31 | -$662.78K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | -$1.17M derived: sum of 2 quarters · filed 2018-03-19 | -$2.40M derived: sum of 3 quarters · filed 2018-03-19 | -$3.55M 10-K · filed 2018-03-19 | |||
| 2016-09-30 | -$511.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$1.74M derived: sum of 2 quarters · filed 2017-11-14 | -$2.89M 10-Q · filed 2017-11-14 | -$4.00M derived: sum of 4 quarters · filed 2017-11-14 | |||
| 2016-06-30 | -$1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | -$2.38M 10-Q · filed 2017-08-11 | -$3.49M derived: sum of 3 quarters · filed 2017-08-11 | -$4.79M derived: sum of 4 quarters · filed 2017-08-11 | |||
| 2016-03-31 | -$1.15M 10-Q · filed 2017-05-12 | -$2.26M derived: sum of 2 quarters · filed 2017-05-12 | -$3.56M derived: sum of 3 quarters · filed 2017-05-12 | -$4.12M derived: sum of 4 quarters · filed 2017-05-12 | |||
| 2015-12-31 | -$1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$2.41M derived: sum of 2 quarters · filed 2017-03-10 | -$2.98M derived: sum of 3 quarters · filed 2017-03-10 | -$3.73M 10-K · filed 2017-03-10 | |||
| 2015-09-30 | -$1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$1.86M derived: sum of 2 quarters · filed 2016-11-09 | -$2.61M 10-Q · filed 2016-11-09 | -$3.42M derived: sum of 4 quarters · filed 2016-11-09 | |||
| 2015-06-30 | -$567.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-12 | -$1.32M 10-Q · filed 2016-08-12 | -$2.12M derived: sum of 3 quarters · filed 2016-08-12 | -$2.71M derived: sum of 4 quarters · filed 2016-08-12 | |||
| 2015-03-31 | -$751.69K 10-Q · filed 2016-05-13 | -$1.55M derived: sum of 2 quarters · filed 2016-05-13 | -$2.15M derived: sum of 3 quarters · filed 2016-05-13 | ||||
| 2014-12-31 | -$802.64K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | -$1.39M derived: sum of 2 quarters · filed 2016-03-21 | -$1.76M 10-K · filed 2016-03-21 | ||||
| 2014-09-30 | -$591.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$952.57K 10-Q · filed 2015-11-12 | |||||
| 2014-07-31 | $7.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-09-15 | $11.24K derived: sum of 2 quarters · filed 2014-09-15 | $7.09K 10-Q · filed 2014-09-15 | -$1.66K derived: sum of 4 quarters · filed 2014-09-15 | |||
| 2014-06-30 | -$361.49K 10-Q · filed 2015-08-14 | ||||||
| 2014-04-30 | $3.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-06-05 | -$832.00 10-Q · filed 2014-06-05 | -$9.59K derived: sum of 3 quarters · filed 2014-06-05 | -$1.38K derived: sum of 4 quarters · filed 2014-09-15 | |||
| 2014-01-31 | -$4.14K 10-Q · filed 2014-03-17 | -$12.90K derived: sum of 2 quarters · filed 2014-03-17 | -$4.69K derived: sum of 3 quarters · filed 2014-09-15 | -$6.15K derived: sum of 4 quarters · filed 2014-09-15 | |||
| 2013-10-31 | -$8.76K derived: 10-K 12 month − 10-Q 9 month · filed 2014-01-27 | -$545.00 derived: sum of 2 quarters · filed 2014-09-15 | -$2.01K derived: sum of 3 quarters · filed 2014-09-15 | -$14.49K 10-K · filed 2014-01-27 | |||
| 2013-07-31 | $8.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-09-15 | $6.75K derived: sum of 2 quarters · filed 2014-09-15 | -$5.74K 10-Q · filed 2014-09-15 | -$6.60K 10-Q · filed 2013-09-16 | -$4.21K derived: sum of 4 quarters · filed 2014-09-15 | -$8.72K 10-Q · filed 2013-09-16 | |
| 2013-04-30 | -$1.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-06-05 | -$13.95K 10-Q · filed 2014-06-05 | -$12.43K derived: sum of 3 quarters · filed 2014-06-05 | -$12.37K derived: sum of 4 quarters · filed 2014-06-05 | -$16.07K 10-Q · filed 2013-06-27 | ||
| 2013-01-31 | -$12.49K 10-Q · filed 2014-03-17 | -$10.96K derived: sum of 2 quarters · filed 2014-03-17 | -$10.91K derived: sum of 3 quarters · filed 2014-03-17 | ||||
| 2012-10-31 | $1.52K derived: 10-K 12 month − 10-Q 9 month · filed 2014-01-27 | $1.58K derived: sum of 2 quarters · filed 2014-01-27 | $1.93K 10-K · filed 2014-01-27 | ||||
| 2012-07-31 | $55.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-09-16 | $403.00 10-Q · filed 2013-09-16 | |||||
| 2012-04-30 | $348.00 10-Q · filed 2013-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |